ClinicalTrials.gg
Not yet recruitingNCT07922980FTEXESUpdated Nov 6, 2026

Usability of the FTEXES Wearable Textile Platform for Functional Electrical Stimulation and EMG

An interventional study of FTEXES wearable system in Motor Disorders, Neuromuscular Diseases and Healthy Volunteers, sponsored by Politecnico di Milano. Not yet recruiting at 1 site in Italy. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Politecnico di Milano · Not applicable, Interventional, and Other

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Study summary

FTEXES (Functionalized TEXtiles for Electrical Stimulation) is a wearable platform based on sensorized garments (Smart Pants and Smart T-shirt) with integrated textile electrodes for surface electromyography (EMG) recording and functional electrical stimulation (FES). This single-center, open-label, non-randomized study evaluates the usability of the system in a controlled laboratory setting. Fifteen participants (5 healthy adults, 5 patients with neuromotor disability, 5 healthcare professionals) take part in a single 45-60 minute session including donning, system setup, calibration, functional tasks (gait for the lower limb; reaching and grasping for the upper limb), doffing and skin inspection. Comfort, skin tolerability, stimulation-related discomfort, perceived usability, satisfaction and acceptability are assessed with standardized questionnaires. The quality of EMG signals recorded with textile electrodes is evaluated as a secondary objective. The study has no therapeutic purpose for individual participants.

02

Conditions studied

  • Motor Disorders
  • Neuromuscular Diseases
  • Healthy Volunteers

Keywords

  • functional electrical stimulation
  • surface electromyography
  • smart textiles
  • wearable devices
  • textile electrodes
  • usability
  • rehabilitation
03

In context

Motor Disorders

73 studies on the registry are indexed under Motor Disorders; 24 are open to participants now.

This study's planned enrollment of 15 is below the median of 41 across 52 interventional studies indexed under Motor Disorders.

Browse Motor Disorders studies →

Lead sponsor

Politecnico di Milano is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults: age 18 years or older; no neuromotor disability; written .
  • Patients: age 18 years or older, or 12-17 years with parental/guardian consent and minor's assent; neuromotor disability compatible with the use of the FTEXES system; indication for FES confirmed by a physiatrist. Previous FES experience is not required.
  • Healthcare professionals: professional qualification consistent with study activities (physiotherapist or physiatrist).

Exclusion criteria

Exclusion Criteria:

  • Missing (for minors: missing parental/guardian consent and/or minor's assent).
  • Inability to understand study aims and procedures or to follow instructions.
  • Clinical, functional, cognitive, behavioral or skin conditions that make participation unsafe or inappropriate, in the investigator's judgment.
  • Skin lesions, abrasions, dermatitis, irritation, infection or other dermatological conditions in device contact areas.
  • Healthy adults: known neuromuscular disease, recent trauma, direct involvement in FTEXES development, or professional/academic dependency on the Principal Investigator.
  • Patients: absence of motor disability compatible with the FTEXES system, or no indication for / unsuitability to FES in the physiatrist's judgment.
  • Healthcare professionals: lack of professional qualification or of competence in the use/configuration of FES systems.
  • Any other condition that, in the investigator's judgment, may interfere with study conduct or endpoint assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Healthy adults

    Five adults aged 18 years or older without neuromotor disability use the FTEXES system in a single session.

    Device: FTEXES wearable system

  • Experimental
    Patients with neuromotor disability

    Five patients aged 12 years or older with neuromotor disability compatible with FES, as assessed by a physiatrist, use the FTEXES system in a single session.

    Device: FTEXES wearable system

  • Other
    Healthcare professionals

    Five healthcare professionals (3 physiotherapists, 2 physiatrists) configure and operate the FTEXES system and evaluate its usability from the operator's perspective.

    Device: FTEXES wearable system

Interventions

  • DeviceFTEXES wearable system

    Sensorized textile garments (Smart Pants for the lower limb, Smart T-shirt for the upper limb) with integrated textile electrodes, connected to a CE-marked FES stimulator (HASOMED RehaMove3) and a CE-marked surface EMG system (FreeEMG 1000). Single session of about 45-60 minutes: donning, setup, calibration, functional tasks (gait cycle or reaching/grasping), doffing and skin inspection.

06

What researchers measure

Primary outcomes

  1. Perceived usability: System Usability Scale (SUS) score

    SUS is a 10-item questionnaire scored from 0 to 100; higher scores indicate better perceived usability.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  2. Wearable comfort: Comfort Rating Scale (CRS) score

    Comfort of the textile garments and textile electrodes assessed with the Comfort Rating Scale (CRS); higher scores indicate greater discomfort.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  3. Stimulation-related pain/discomfort (NRS/VAS 0-10)

    Global and localized discomfort, perceived fatigue and pain associated with functional electrical stimulation, rated on a 0-10 numeric/visual analogue scale; 0 = none, 10 = worst imaginable.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  4. Satisfaction with the assistive device: adapted QUEST 2.0

    Satisfaction with the FTEXES system assessed with an adapted version of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0); items scored 1-5, higher scores indicate greater satisfaction.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  5. Acceptability and intention to use: Net Promoter Score (NPS) and intention-to-use questionnaire

    Likelihood to recommend the system (NPS, 0-10 rating, summarized as -100 to +100) and intention to use the platform in the future, including at home.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

Secondary outcomes

  1. Coherence score (0.0-1.0) of EMG signal quality: amplitude and frequency spectrum

    Coherence score (0.0 if signal amplitude \<50% of amplitude with standard Ag/AgCl electrodes -1.0 = signal amplitude = 100% of amplitude with standard Ag/AgCl electrodes) of Amplitude and frequency spectrum (% coveragle of signal spectrum) of surface EMG signals recorded with the textile electrodes of the FTEXES garments.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  2. FES artifact rejection in EMG signals

    Effectiveness of rejection of functional electrical stimulation artifacts in surface EMG signals recorded during stimulation scored as number number of artifacts recorded as number of artifacts out of 10 test events.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

Other outcomes

  1. Skin tolerability: visual skin inspection

    Presence of redness, pressure marks, abrasions or other skin reactions in device contact areas, assessed by visual inspection at the end of the session.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  2. Number of participants with adverse events

    Adverse events recorded during the session using the study adverse event form.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

  3. Donning and setup performance

    Time to don/doff the garments and connect/configure the system, level of assistance required and number of non-critical procedural errors, assessed by observation.

    Time frame: During and at the end of the single experimental session (approximately 60 minutes)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07922980
Lead sponsor
Politecnico di Milano
Collaborators
IRCCS Eugenio Medea
Responsible party
Giuseppe Andreoni (Researcher, Principal Investigator, Politecnico di Milano) — Principal investigator
First posted
Nov 6, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Leonardo Boccuni, PhD
Contact
leonardo.boccuni@lanostrafamiglia.it
+39 031 877111
Leonardo Boccuni, PhD
principal investigator · IRCCS Eugenio Medea
Giuseppe Andreoni
study chair · Politecnico di Milano

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion